ZJK fell -4.62% during regular market hours, trading around $1.65 versus the prior session's $1.73 close. The decline was not tied to company-specific news, reflecting continued thin-volume selling in this low-float micro-cap name.

GOAI fell -5.23% to about $1.45, down from its prior session close of $1.53. The decline occurred during regular market hours on October 23.

B&G Foods (BGS) is trading down -5.12% intraday during regular market hours, slipping from a prior close of $2.15 to roughly $2.04. The decline extends a prolonged slide, with shares down about -35% over the past three months versus a roughly flat consumer staples industry.

QNC is trading down -5.17% to $1.10 during regular NYSE American hours, versus the prior session's $1.16 close. The decline reflects ongoing dilution concerns around the proposed Plurilock acquisition, where roughly 70% of consideration is paid in QNC stock.

SHMD is trading down roughly -4.66% during regular market hours, extending a sharp multi-week decline. The slide follows the company's cut to its 2026 adjusted EBITDA margin guidance (from above 12% to 6%–9%) on a lower-margin China production shift.

LANV closed at $0.84 on Oct 22, down -4.44% (-$0.039) from the prior session's $0.879 close, with the decline occurring during regular market hours. No single company-specific catalyst emerged; the move extends a sustained downtrend in this thinly traded luxury micro-cap, which remains down roughly -50% year-to-date.

INDI is trading down -5.36% intraday to about $1.59, extending losses from Wednesday's $1.68 close during regular market hours. Primary catalyst is analyst capitulation, with TD Cowen cutting its target to $2.00 from $4.50 (Hold) and B. Riley lowering to $5 from $6, pressuring sentiment.

ABOS is trading down -4.85% to $1.96 during regular market hours, retreating from the prior session's $2.06 close. The decline reflects pre-earnings caution with no major company-specific headline, following several sessions of gains earlier in the week.

MMLP fell -5.53% during regular market hours, with the last trade at $2.045 versus the prior session's $2.17 close. The decline tracked broad weakness across midstream and energy peers as crude oil prices retreated and rising Treasury yields pressured risk assets sector-wide.

AIFU Inc. (AIFU) is trading down -5.56% during regular market hours, last at $10.70 versus the prior session close of $11.33. The decline follows ongoing dilution concerns tied to a $135 million private placement priced at a deep discount in mid-October.

Equillium (EQ) fell -4.72% during regular trading, sliding from a $1.27 prior close to about $1.21. The move extends a sharp multi-session downtrend, following a -10.56% drop on Oct 22 that broke below both the 50-day and 200-day moving averages.

PDS Biotech (PDSB) is trading down -6.03% to about $1.09 during regular market hours, extending the prior session's -6.45% decline. The move reflects profit-taking after an outsized speculative rally; shares surged +29% on Oct 21 and touched $1.79 earlier in October.

BDTX is trading down -8.65% to $1.90 during regular market hours, versus its prior close of $2.08. The decline follows mixed Phase II data for its lead silevertinib program in frontline EGFR-mutant NSCLC, weighing on investor sentiment.

SES AI (SES) is trading down roughly -8.22% to about $0.67 during regular session hours, giving back part of the prior session's +15.21% surge. No company-specific negative news emerged today; the decline reflects profit-taking following the Oct. 22 rally sparked by the Chungju drone-battery plant ramp to one million NDAA-compliant cells and expansion plans to three million by Q2 2027.

PTHS is trading down -6.58% (roughly -$1.29) to $18.30 during regular market hours, after closing the prior session at $19.59. No single company-specific catalyst has been confirmed; the move reflects continued selling pressure following an -8.7% drop earlier in the week.

ADCT is trading down -6.25% to roughly $1.50 during regular market hours, versus a prior-session close of $1.60. The decline follows continued pressure from recent FDA feedback flagging "substantial concerns" over the benefit-risk profile of the LOTIS-5 Phase 3 ZYNLONTA data, with the company still assessing its regulatory path.

EDIT is down -5.62% during the regular session, falling from a $2.49 prior close to roughly $2.35. The primary catalyst was sector-wide pressure after Anthropic shared early findings on a CRISPR-like enzyme system, hitting gene-editing peers.

ASPI fell -5.26% in regular trading, sliding to roughly $1.98 from a $2.09 prior close. The move extends a downtrend driven by share-dilution concerns after Quantum Leap Energy notes converted into about 23.2 million shares.

AIIO (Robo.ai Inc.) fell -8.13% during regular trading hours to roughly $0.55, down from the prior session's close of $0.60. The decline occurred in intraday market-hours trading, extending a prolonged multi-week slide for the volatile micro-cap.

OVID is trading down -8.02% intraday to roughly $2.18 during regular session hours, extending the prior session's -4.05% decline. The pullback follows a sharp two-day run (+8.76% and +4.66%) and appears driven by profit-taking, with no company-specific headline behind the move.